Episode 4: Treatment Choices in Front Line Advanced Renal Cancer
Dr. Brian Rini and Professor Tom Powles ask David McDermott about how he chooses between ipilimumab/nivolumab or axitinib/pebrolizumab intreatment options
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"The Uromigos","authorlink":""},"src":"https:\/\/anchor.fm\/s\/13347ea8\/podcast\/play\/10316577\/https:\/\/d3ctxlq1ktw2nl.cloudfront.net\/production\/2020-1-11\/48003845-44100-2-b4a9cbcb29bf6.mp3","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202106\/5a775e-0e9b-d998-92efa1_800.jpg"},"title":"Episode 4: Treatment Choices in Front Line Advanced Renal Cancer","link":"javascript:;","id":"item-691337"}]
